Creative Biolabs Introduces One-stop SARS-CoV-2 Antiviral Drug Discovery Services

To advance the research and development of COVID-19 prevention and treatment, the scientist team at Creative Biolabs has introduced the one-stop SARS-CoV-2 antiviral drug discovery.

New York, USA – August 17, 2020 – As 8 months have passed by since the first outbreak of COVID-19, the confirmed cases are still growing rapidly. Confronted by this severe epidemic situation, Creative Biolabs has taken immediate actions to facilitate the research and development of specific drugs by releasing one-stop SARS-CoV-2 antiviral drug discovery.

• Antiviral Agents-Inhibitors

SARS-CoV-2 is a newly identified coronavirus with a positive-sense, single-stranded RNA. Amino acid sequence conservation of the RNA-dependent RNA polymerase of coronavirus is relative higher than others, suggesting that nucleoside analogue may be effective in treatment of SARS-CoV-2 infections.

Considering different kinds of nucleoside analogue has different characteristics, Creative Biolabs provides a pipeline of R&D services of antiviral nucleoside analogues based on multiple action mechanisms, including Remdesivir, NHC, BCX4430, Gemcitabine Hydrochloride, 6-Azauridine, Mizoribine, Acyclovir Fleximer, and Ribavirin for SARS-CoV-2 treatment research.

Apart from nucleoside analogue inhibitors, Creative Biolabs also provides services of viral protease inhibitors, inhibitors of host cell protease, Abelson kinase inhibitors, RNA synthesis inhibitors, and neuraminidase inhibitors.

• Antiviral Agents-Broad-spectrum Antiviral Drugs

The broad-spectrum antiviral drug is able to stop the virus from replicating or reproducing in infected cells, as well as improving cellular defence system, thus possible to be effective in the treatment of SARS-CoV-2 infection. For example, interferons (IFNs), including IFN-alpha and IFN-beta produced by infected cells, have shown antiviral activities and the ability to induce various kinds of immunological activities, revealing that IFN-ß for SARS-CoV-2 may be one of the research directions.

With state-of-art computer-aided drug development platform as well as advanced bioinformatics technologies, Creative Biolabs is confident to provide comprehensive preclinical and clinical development services and solutions for antiviral drugs from research design, lead optimization to IND enabling.

• Antiviral Agents-Antibodies and Peptides

With extensive antibody development and manufacturing experience in the fields of infections, expert team of Creative Biolabs is committed to the development of neutralizing antibodies and the main antibody development covers the subjects of CR3022, CD4, and glycoprotein.

Antiviral peptide discovery services provided by Creative Biolabs include peptide microarray analysis service for SARS-CoV-2, fusion peptide (EK1) and ACE2-based peptide for SARS-CoV-2 treatment.

In addition, Creative Biolabs also has more than a decade of experience and deep expertise in vaccine discovery and development, and is committed to vaccine discovery services for SARS-CoV-2, including live attenuated and SARS-CoV-2 killed vaccine development, in Silico vaccine design, mRNA vaccine development, recombinant subunit vaccine development, etc.

More information can be found on

About Creative Biolabs

Empowered by leading technology and over 15 years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements with accumulated experience in drug discovery and vaccine development. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.

Media Contact
Company Name: Creative Biolabs
Contact Person: Bella Smith
Email: Send Email
Phone: 1-631-619-7922
Country: United States